Effect of Once-Weekly Dulaglutide on Glucose Levels in Japanese Patients with Type 2 Diabetes: Findings from a Phase 4, Randomized Controlled Trial

INTRODUCTION: Dulaglutide is a recombinant glucagon-like peptide-1 immunoglobulin G4 Fc fusion protein approved for treating patients with type 2 diabetes (T2D). The aim of this study was to assess postprandial data over 4 weeks for dulaglutide (0.75 mg) versus placebo after a standardized test meal...

Descripción completa

Detalles Bibliográficos
Autores principales: Inoue, Megumi, Shiramoto, Masanari, Oura, Tomonori, Nasu, Risa, Nakano, Masako, Takeuchi, Masakazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531535/
https://www.ncbi.nlm.nih.gov/pubmed/30949907
http://dx.doi.org/10.1007/s13300-019-0605-7